Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. (ITCI): 10 pipeline candidates · ~14 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
13.9 months
D/E 0.19 · 0% dilution
Lead: Approved
10 candidates
N/A
N/A
A transparent, data-derived signal for Intra-Cellular Therapies, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$9.0B
Cash
$308.7M
Quarterly Burn
$228.4M
Runway
13.9 mo
Revenue
$199.2M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| Caplyta | Approved |
| ITI-1020 | Phase 1 |
| iti-1284 | Phase 1 |
| ITI-1284-ODT-SL | Phase 2 |
| ITI-1549 | Phase 1 |
| ITI-333 | Phase 1 |
| lenrispodun | Phase 2 |
| lenrispodun (ITI-214) | Phase 2 |
| lumateperone | Phase 3 |
| lumateperone LAI | Phase 3 |
Frequently asked questions
How many drug candidates are in Intra-Cellular Therapies, Inc.'s pipeline?
Intra-Cellular Therapies, Inc. (ITCI) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Intra-Cellular Therapies, Inc.'s lead drug candidate?
Intra-Cellular Therapies, Inc.'s most advanced tracked candidate is Caplyta (Approved) for Schizophrenia (adults); Bipolar depression (adults).
What is Intra-Cellular Therapies, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Intra-Cellular Therapies, Inc. has approximately 13.9 months of cash runway.
What is Intra-Cellular Therapies, Inc.'s market capitalization?
Intra-Cellular Therapies, Inc.'s market capitalization is approximately $9.0B.
Who is the CEO of Intra-Cellular Therapies, Inc.?
Chief Executive Officer is the chief executive officer of Intra-Cellular Therapies, Inc. (ITCI).
Get the full picture on Intra-Cellular Therapies, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.